306 related articles for article (PubMed ID: 15561844)
1. TMC125, a novel next-generation nonnucleoside reverse transcriptase inhibitor active against nonnucleoside reverse transcriptase inhibitor-resistant human immunodeficiency virus type 1.
Andries K; Azijn H; Thielemans T; Ludovici D; Kukla M; Heeres J; Janssen P; De Corte B; Vingerhoets J; Pauwels R; de Béthune MP
Antimicrob Agents Chemother; 2004 Dec; 48(12):4680-6. PubMed ID: 15561844
[TBL] [Abstract][Full Text] [Related]
2. TMC125 displays a high genetic barrier to the development of resistance: evidence from in vitro selection experiments.
Vingerhoets J; Azijn H; Fransen E; De Baere I; Smeulders L; Jochmans D; Andries K; Pauwels R; de Béthune MP
J Virol; 2005 Oct; 79(20):12773-82. PubMed ID: 16188980
[TBL] [Abstract][Full Text] [Related]
3. The HEPT Analogue WPR-6 Is Active against a Broad Spectrum of Nonnucleoside Reverse Transcriptase Drug-Resistant HIV-1 Strains of Different Serotypes.
Xu W; Zhao J; Sun J; Yin Q; Wang Y; Jiao Y; Liu J; Jiang S; Shao Y; Wang X; Ma L
Antimicrob Agents Chemother; 2015 Aug; 59(8):4882-8. PubMed ID: 26055365
[TBL] [Abstract][Full Text] [Related]
4. Characteristics of a group of nonnucleoside reverse transcriptase inhibitors with structural diversity and potent anti-human immunodeficiency virus activity.
Yang SS; Fliakas-Boltz V; Bader JP; Buckheit RW
Leukemia; 1995 Oct; 9 Suppl 1():S75-85. PubMed ID: 7475321
[TBL] [Abstract][Full Text] [Related]
5. Impact of reverse transcriptase resistance on the efficacy of TMC125 (etravirine) with two nucleoside reverse transcriptase inhibitors in protease inhibitor-naïve, nonnucleoside reverse transcriptase inhibitor-experienced patients: study TMC125-C227.
Ruxrungtham K; Pedro RJ; Latiff GH; Conradie F; Domingo P; Lupo S; Pumpradit W; Vingerhoets JH; Peeters M; Peeters I; Kakuda TN; De Smedt G; Woodfall B;
HIV Med; 2008 Nov; 9(10):883-96. PubMed ID: 18795960
[TBL] [Abstract][Full Text] [Related]
6. Antiviral activity of GW678248, a novel benzophenone nonnucleoside reverse transcriptase inhibitor.
Ferris RG; Hazen RJ; Roberts GB; St Clair MH; Chan JH; Romines KR; Freeman GA; Tidwell JH; Schaller LT; Cowan JR; Short SA; Weaver KL; Selleseth DW; Moniri KR; Boone LR
Antimicrob Agents Chemother; 2005 Oct; 49(10):4046-51. PubMed ID: 16189079
[TBL] [Abstract][Full Text] [Related]
7. Structure-activity relationship studies of novel benzophenones leading to the discovery of a potent, next generation HIV nonnucleoside reverse transcriptase inhibitor.
Romines KR; Freeman GA; Schaller LT; Cowan JR; Gonzales SS; Tidwell JH; Andrews CW; Stammers DK; Hazen RJ; Ferris RG; Short SA; Chan JH; Boone LR
J Med Chem; 2006 Jan; 49(2):727-39. PubMed ID: 16420058
[TBL] [Abstract][Full Text] [Related]
8. Modulation of human immunodeficiency virus type 1 synergistic inhibition by reverse transcriptase mutations.
Basavapathruni A; Vingerhoets J; de Béthune MP; Chung R; Bailey CM; Kim J; Anderson KS
Biochemistry; 2006 Jun; 45(23):7334-40. PubMed ID: 16752922
[TBL] [Abstract][Full Text] [Related]
9. Etravirine: a second-generation nonnucleoside reverse transcriptase inhibitor (NNRTI) active against NNRTI-resistant strains of HIV.
Schiller DS; Youssef-Bessler M
Clin Ther; 2009 Apr; 31(4):692-704. PubMed ID: 19446143
[TBL] [Abstract][Full Text] [Related]
10. Differential impact of the HIV-1 non-nucleoside reverse transcriptase inhibitor mutations K103N and M230L on viral replication and enzyme function.
Xu HT; Oliveira M; Quan Y; Bar-Magen T; Wainberg MA
J Antimicrob Chemother; 2010 Nov; 65(11):2291-9. PubMed ID: 20852269
[TBL] [Abstract][Full Text] [Related]
11. TMC278, a next-generation nonnucleoside reverse transcriptase inhibitor (NNRTI), active against wild-type and NNRTI-resistant HIV-1.
Azijn H; Tirry I; Vingerhoets J; de Béthune MP; Kraus G; Boven K; Jochmans D; Van Craenenbroeck E; Picchio G; Rimsky LT
Antimicrob Agents Chemother; 2010 Feb; 54(2):718-27. PubMed ID: 19933797
[TBL] [Abstract][Full Text] [Related]
12. The phenylmethylthiazolylthiourea nonnucleoside reverse transcriptase (RT) inhibitor MSK-076 selects for a resistance mutation in the active site of human immunodeficiency virus type 2 RT.
Auwerx J; Stevens M; Van Rompay AR; Bird LE; Ren J; De Clercq E; Oberg B; Stammers DK; Karlsson A; Balzarini J
J Virol; 2004 Jul; 78(14):7427-37. PubMed ID: 15220416
[TBL] [Abstract][Full Text] [Related]
13. In vitro selection of mutations in human immunodeficiency virus type 1 reverse transcriptase that confer resistance to capravirine, a novel nonnucleoside reverse transcriptase inhibitor.
Sato A; Hammond J; Alexander TN; Graham JP; Binford S; Sugita K; Sugimoto H; Fujiwara T; Patick AK
Antiviral Res; 2006 Jun; 70(2):66-74. PubMed ID: 16472877
[TBL] [Abstract][Full Text] [Related]
14. Novel pyridinone derivatives as non-nucleoside reverse transcriptase inhibitors (NNRTIs) with high potency against NNRTI-resistant HIV-1 strains.
Li A; Ouyang Y; Wang Z; Cao Y; Liu X; Ran L; Li C; Li L; Zhang L; Qiao K; Xu W; Huang Y; Zhang Z; Tian C; Liu Z; Jiang S; Shao Y; Du Y; Ma L; Wang X; Liu J
J Med Chem; 2013 May; 56(9):3593-608. PubMed ID: 23540737
[TBL] [Abstract][Full Text] [Related]
15. In vitro characterization of a simian immunodeficiency virus-human immunodeficiency virus (HIV) chimera expressing HIV type 1 reverse transcriptase to study antiviral resistance in pigtail macaques.
Ambrose Z; Boltz V; Palmer S; Coffin JM; Hughes SH; Kewalramani VN
J Virol; 2004 Dec; 78(24):13553-61. PubMed ID: 15564466
[TBL] [Abstract][Full Text] [Related]
16. [Discovery and development of diarylpyrimidines (DAPYs) as next-generation HIV-1 non-nucleoside reverse transcriptase inhibitors (NNRTIs)].
Tian XT; Xie L
Yao Xue Xue Bao; 2010 Feb; 45(2):177-83. PubMed ID: 21351427
[TBL] [Abstract][Full Text] [Related]
17. Antiviral activity of MK-4965, a novel nonnucleoside reverse transcriptase inhibitor.
Lai MT; Munshi V; Touch S; Tynebor RM; Tucker TJ; McKenna PM; Williams TM; DiStefano DJ; Hazuda DJ; Miller MD
Antimicrob Agents Chemother; 2009 Jun; 53(6):2424-31. PubMed ID: 19289522
[TBL] [Abstract][Full Text] [Related]
18. Anti-human immunodeficiency virus type 1 activity of the nonnucleoside reverse transcriptase inhibitor GW678248 in combination with other antiretrovirals against clinical isolate viruses and in vitro selection for resistance.
Hazen RJ; Harvey RJ; St Clair MH; Ferris RG; Freeman GA; Tidwell JH; Schaller LT; Cowan JR; Short SA; Romines KR; Chan JH; Boone LR
Antimicrob Agents Chemother; 2005 Nov; 49(11):4465-73. PubMed ID: 16251284
[TBL] [Abstract][Full Text] [Related]
19. Novel benzophenones as non-nucleoside reverse transcriptase inhibitors of HIV-1.
Chan JH; Freeman GA; Tidwell JH; Romines KR; Schaller LT; Cowan JR; Gonzales SS; Lowell GS; Andrews CW; Reynolds DJ; St Clair M; Hazen RJ; Ferris RG; Creech KL; Roberts GB; Short SA; Weaver K; Koszalka GW; Boone LR
J Med Chem; 2004 Feb; 47(5):1175-82. PubMed ID: 14971897
[TBL] [Abstract][Full Text] [Related]
20. Synthesis and biological activity of novel nonnucleoside inhibitors of HIV-1 reverse transcriptase. 2-Aryl-substituted benzimidazoles.
Roth T; Morningstar ML; Boyer PL; Hughes SH; Buckheit RW; Michejda CJ
J Med Chem; 1997 Dec; 40(26):4199-207. PubMed ID: 9435891
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]